Evidence map›Paper›PMID 27354024›Full record

ArticleHaematologica2016

Non-Hodgkin lymphoma in the developing world: review of 4539 cases from the International Non-Hodgkin Lymphoma Classification Project.

Anamarija M Perry, Jacques Diebold, Bharat N Nathwani, Kenneth A MacLennan, Hans K Müller-Hermelink, Martin Bast, Eugene Boilesen, James O Armitage, Dennis D Weisenburger

Abstract readMulticenter Study
In one paragraph

Article in Haematologica, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 92 papers.

0numbers the graph read from it
0cells of the map it votes in
92citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

92 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

32 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Anamarija M PerryDepartment of Pathology, University of Manitoba, Winnipeg, Manitoba, Canada.
Jacques DieboldDepartment of Anatomic Pathology and Cytology, Hotel-Dieu, University Denis Diderot, Paris, France.
Bharat N NathwaniDepartment of Pathology, City of Hope National Medical Center, Duarte, CA, USA.
Kenneth A MacLennanSection of Pathology and Leeds Institute of Molecular Medicine, St. James University Hospital, Leeds, UK.
Hans K Müller-HermelinkInstitute of Pathology, University of Würzburg, Germany.
Martin BastDepartment of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
Eugene BoilesenCenter for Collaboration on Research Design and Analysis, College of Public Health, University of Nebraska Medical Center, Omaha, NE, USA.
James O ArmitageDepartment of Pathology, University of Manitoba, Winnipeg, Manitoba, Canada.
Dennis D WeisenburgerDepartment of Pathology, City of Hope National Medical Center, Duarte, CA, USA dweisenburger@coh.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The distribution of non-Hodgkin lymphoma subtypes varies around the world, but a large systematic comparative study has never been done. In this study, we evaluated the clinical features and relative frequencies of non-Hodgkin lymphoma subtypes in five developing regions of the world and compared the findings to the developed world. Five expert hematopathologists classified 4848 consecutive cases of lymphoma from 26 centers in 24 countries using the World Health Organization classification, and 4539 (93.6%) were confirmed to be non-Hodgkin lymphoma, with a significantly greater number of males than females in the developing regions compared to the developed world (P<0.05). The median age at diagnosis was significantly lower for both low- and high-grade B-cell lymphoma in the developing regions. The developing regions had a significantly lower frequency of B-cell lymphoma (86.6%) and a higher frequency of T- and natural killer-cell lymphoma (13.4%) compared to the developed world (90.7% and 9.3%, respectively). Also, the developing regions had significantly more cases of high-grade B-cell lymphoma (59.6%) and fewer cases of low-grade B-cell lymphoma (22.7%) compared to the developed world (39.2% and 32.7%, respectively). Among the B-cell lymphomas, diffuse large B-cell lymphoma was the most common subtype (42.5%) in the developing regions. Burkitt lymphoma (2.2%), precursor B- and T-lymphoblastic leukemia/lymphoma (1.1% and 2.9%, respectively) and extranodal natural killer/T-cell lymphoma (2.2%) were also significantly increased in the developing regions. These findings suggest that differences in etiologic and host risk factors are likely responsible, and more detailed epidemiological studies are needed to better understand these differences.

Indexed as

AdolescentAdultAgedAged, 80 and overAge FactorsChildChild, PreschoolDeveloped CountriesDeveloping CountriesFemaleHumansInfantLymphoma, B-CellLymphoma, Non-HodgkinMaleMiddle Aged

Identifiers

PMID27354024
PMCPMC5046654

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.